Elevation Oncology, Inc. announced on December 12, 2024, that it has entered into a licensing agreement with Synaffix B.V. This agreement grants Elevation Oncology global access to Synaffix's clinical-stage, site-specific ADC technology platform.
The licensed platform includes GlycoConnect® antibody conjugation technology, HydraSpace® polar spacer technology, and the toxSYN® linker-payload, SYNstatin E™. This technology is intended to enable the development of differentiated ADCs with an improved therapeutic index.
Under the terms of the agreement, Synaffix is eligible to receive up to $368 million in upfront and clinical, regulatory, and commercial milestone payments, plus tiered royalties on net sales. Elevation Oncology will be responsible for the research, development, manufacturing, and commercialization of ADCs utilizing this platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.